Open AccessPharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Author(s) -
Leipold Douglas,
Prabhu Saileta
Publication year - 2019
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12597
Subject(s) - pharmacodynamics , pharmacokinetics , monoclonal antibody , pharmacology , medicine , antibody , adverse effect , therapeutic index , computational biology , drug , immunology , biology
The design and development of therapeutic monoclonal antibodies (mAbs) through optimizing their pharmacokinetic ( PK ) and pharmacodynamic ( PD ) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challenges in therapeutic antibody design, where improving one antibody property can sometimes lead to changes in others. Here, we discuss optimization approaches for PK / PD properties of therapeutic mA bs.